Recombinant Mouse Acox2 protein, His & T7-tagged

• Cat.No.: Acox2-8161M
• Product Overview: Recombinant Mouse Acox2 aa. (Leu49~Thr308 (Accession # Q3UNF3)) fused with N-terminal His & T7 tag was produced in E. coli cells.

Specification

• Source: E. coli
• Species: Mouse
• Tag: His & T7
• Form: Freeze-dried powder
• Molecular Mass: Predicted Molecular Mass: 33.2kDa.
• Protein length: Leu49~Thr308 (Accession # Q3UNF3)
• Endotoxin: <1.0EU per 1ug (determined by the LAL method)
• Purity: >95%
• Characteristic: The isoelectric point is 6.6.
• Applications: SDS-PAGE; WB; ELISA; IP.
• Stability: The thermal stability is described by the loss rate of the target protein. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. (Referring from China Biological Products Standard, which was calculated by the Arrhenius equation.) The loss of this protein is less than 5% within the expiration date under appropriate storage condition.
• Storage: Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.
• Storage Buffer: Supplied as lyophilized form in 20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% sarcosyl, 5% trehalose, and preservative.
• Reconstitution: Reconstitute in sterile ddH2O.

Gene Information

• Gene Name: Acox2 acyl-Coenzyme A oxidase 2, branched chain [ Mus musculus (house mouse) ]
• Official Symbol: Acox2
• Gene ID: 93732
• mRNA Refseq: NM_001161667.1
• Protein Refseq: NP_001155139.1
• UniProt ID: Q3UNF3

Q&As

Can ACOX2 be used as a target for drug development?

Yes, ACOX2 has been suggested as a potential target for drug development in metabolic disorders such as nonalcoholic fatty liver disease (NAFLD) and obesity. Inhibition of ACOX2 activity has been shown to decrease lipid accumulation and improve liver function in animal models of NAFLD.

What are the key structural features of ACOX2 protein?

ACOX2 is a member of the acyl-CoA oxidase family of enzymes, which all share a similar structure and mechanism of action. It is a homodimeric protein, with each monomer consisting of three domains: a flavin adenine dinucleotide (FAD)-binding domain, a covalent flavin mononucleotide (FMN)-binding domain, and a so-called "helical domain" that is involved in dimerization. The active site of ACOX2 is located at the interface between the two monomers and contains the catalytic residues necessary for β-oxidation of fatty acids.

What are the potential therapeutic applications of ACOX2 in human medicine?

ACOX2 has potential therapeutic applications in treating diseases associated with abnormal fatty acid metabolism, such as insulin resistance, obesity, and non-alcoholic fatty liver disease (NAFLD). By enhancing ACOX2 activity, it may be possible to increase the breakdown of VLCFAs and BCFAs and reduce the accumulation of toxic metabolites in tissues. Additionally, modulating ACOX2 expression or activity may have implications for the treatment of certain types of cancer, as ACOX2 has been shown to be upregulated in some tumor cells.

Are there any genetic disorders associated with ACOX2 deficiency?

Yes, ACOX2 deficiency is associated with a rare genetic disorder called α-methylacyl-CoA racemase (AMACR) deficiency. This disorder is characterized by the accumulation of 2-methyl-branched fatty acids and bile acid intermediates, which can lead to neurological and developmental abnormalities as well as liver and kidney damage. Defects in ACOX2 activity are thought to be responsible for the impaired breakdown of these fatty acids and the development of AMACR deficiency.

What types of tissues express ACOX2?

ACOX2 is primarily expressed in tissues that are involved in energy metabolism, such as liver, kidney, heart, and muscle. It is also expressed in certain tissues involved in fatty acid metabolism, such as adipose tissue and skin. In the brain, ACOX2 is expressed in oligodendrocytes, cells that produce the myelin sheath that surrounds and protects neurons.

Is ACOX2 involved in cancer development?

The role of ACOX2 in cancer development is not well understood. Some studies have suggested that ACOX2 expression is increased in certain types of cancer, such as gastric cancer, while others have shown decreased expression in breast cancer. More research is needed to determine the potential role of ACOX2 in cancer development and progression.

Can ACOX2 be used as a biomarker for certain diseases or conditions?

ACOX2 levels and activity may serve as a biomarker for certain diseases or conditions, such as NAFLD and prostate cancer. In patients with NAFLD, ACOX2 expression has been shown to be increased, indicating a potential role for ACOX2 in the development and progression of this condition. Similarly, ACOX2 expression has been shown to be elevated in prostate cancer cells, suggesting that it could serve as a marker for this disease.

How is ACOX2 activity regulated in cells?

The activity of ACOX2 is regulated by a number of different factors, including the availability of co-factors such as Coenzyme A (CoA), NAD+, and FAD, as well as the expression and activity of other enzymes in the peroxisomal β-oxidation pathway. ACOX2 expression can also be modulated by signaling pathways such as AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptors (PPARs), which are involved in energy homeostasis.

How is ACOX2 protein studied in the lab?

ACOX2 protein can be studied in the lab through a variety of techniques, including western blotting, immunohistochemistry, and enzyme activity assays. Antibodies can be used to detect the presence and abundance of ACOX2 protein in different tissues and cell types. Enzyme activity assays can be used to measure the catalytic activity of ACOX2 in vitro, using purified protein or cell lysates. In addition, genetically modified mouse models can be used to study the effects of ACOX2 deficiency or overexpression in vivo.

Can ACOX2 be used in biotechnology applications?

Yes, ACOX2 has been used in biotechnology applications such as biofuel production. Expression of ACOX2 can increase fatty acid metabolism in microbes such as yeast, leading to higher production of fatty acids that can be converted to biofuels.

Are there diagnostic applications for ACOX2 protein?

ACOX2 protein levels have been shown to be altered in certain diseases such as NAFLD, suggesting its potential as a diagnostic marker for these conditions. However, further studies are needed to determine the diagnostic utility of ACOX2 in clinical settings.

Could ACOX2 be used as a biomarker for Alzheimer's disease?

Some studies have suggested that ACOX2 expression is altered in the brains of patients with Alzheimer's disease, and that lower levels of ACOX2 may be associated with increased cognitive decline. However, more research is needed to determine the potential utility of ACOX2 as a biomarker for Alzheimer's disease.

Are there any drugs or compounds that target ACOX2 for therapeutic purposes?

Currently, there are no drugs or compounds approved by the FDA that specifically target ACOX2 for therapeutic purposes. However, some studies have identified potential compounds that could modulate ACOX2 activity, such as fenofibrate and clofibrate. These compounds have been shown to increase the expression of ACOX2 and other peroxisomal enzymes involved in fatty acid metabolism, and further research is needed to determine their potential efficacy in human patients.